APOLLO THERAPEUTICS
Live / Registered — Registered (as of 26 Sept 2023)
What this means for you
Registered since 26 Sept 2023. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90798637
- Registration number
- 7172183
- Mark type
- Stylized text
- Filed
- 28 Jun 2021
- Published for opposition
- 11 Apr 2023
- Registered
- 26 Sept 2023
- Attorney of record
- Benjamin Charkow
Goods and services
- Class 005 — Pharmaceuticals: Therapeutic pharmaceuticals for the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases; pharmaceutical preparations, namely biologics, biosimilars, small molecules, gene-engineered cell therapy in the nature of cells for medical use, namely autologous gene-engineered cells; medical preparations for the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases
- Class 035 — Advertising and business services: Collection of data and management of data for business purposes in connection with clinical research, testing, trial and development of pharmaceuticals, therapeutics and medical devices; computerized database management and data processing services in the field of medical, pharmaceutical and therapeutic treatment
- Class 036 — Insurance and financial services: Financial sponsorship in the form of providing financial resources to non-hospital partnerships, associations and companies, to aid in the research, development, production, import, export, retail, wholesale, promotion, commercial distribution and commercialisation of pharmaceutical, therapeutic and medicinal products and preparations
- Class 041 — Education and entertainment services: Education services, namely, providing instruction in the field of pharmaceutical and therapeutic medical education; arranging and conducting of conferences, congresses, courses, in particular in the fields of medicine and pharmaceuticals; publishing services, namely, the publication of periodicals, books, magazines, and articles in the field of medicine, pharmaceuticals, and therapeutics; publication of periodicals, books, magazines, articles, in particular in the fields of medicine, pharmaceuticals and therapeutics
- Class 042 — Scientific and technological services: Scientific, medical and pharmaceutical research and development services; clinical research in the field of the use of biologics, biosimilars, small molecules, gene-engineered cell therapy and vaccines for the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases; pharmaceutical drug development services; scientific investigations for medical purposes; medical laboratory services; laboratory research services related to pharmaceuticals; advisory services relating to medical and pharmaceutical science research in the field of the use of biologics, biosimilars, small molecules, gene-engineered cell therapy and vaccines for the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases; research and development of pharmaceutical preparations
- Class 044 — Medical, beauty and agricultural services: Non-emergency and non-clinical medical and pharmaceutical consulting services related to the use of pharmaceutical preparations, namely biologics, biosimilars, small molecules, gene-engineered cell therapy and vaccines; non-emergency medical analysis services for diagnostic and treatment purposes related to the use of pharmaceutical preparations, namely biologics, biosimilars, small molecules, gene-engineered cell therapy and vaccines, provided by medical laboratories; medical analysis and examination services related to the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases, provided by medical laboratories; medical treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases; advisory services relating to medical and pharmaceutical science, namely, medical advisory services and pharmaceutical advisory services in the field of the use of biologics, biosimilars, small molecules, gene-engineered cell therapy and vaccines for the treatment of cardiovascular diseases, blood disorders, respiratory diseases, asthma, central nervous system disorders, cancer and tumors, diseases and disorders of the autoimmune system, allergies, renal transplant, hypertension, chronic kidney disease, and metabolic diseases
Owner
- APOLLO THERAPEUTICS LIMITED, CAMBRIDGE, GB
- APOLLO THERAPEUTICS NO.2 LLP, LONDON, GB
- APOLLO THERAPEUTICS NO.2 LLP, LONDON, GB
- Apollo Therapeutics LLP, London, GB
- Apollo Therapeutics LLP, London, GB
- Apollo Therapeutics LLP, London, GB
Prosecution history
- 04 Feb 2026 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 26 Nov 2025 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 05 Nov 2025 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 26 Sept 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 26 Sept 2023 — REGISTERED-PRINCIPAL REGISTER
- 21 Aug 2023 — 1(B) BASIS DELETED; PROCEED TO REGISTRATION
- 10 Jul 2023 — NOTICE OF ALLOWANCE CANCELLED
- 21 Aug 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 10 Jul 2023 — TEAS DELETE 1(B) BASIS RECEIVED
- 06 Jun 2023 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 11 Apr 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 11 Apr 2023 — PUBLISHED FOR OPPOSITION
- 22 Mar 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 03 Mar 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 01 Mar 2023 — EXAMINER'S AMENDMENT ENTERED